U.S., Jan. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07321093) titled 'A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis' on Nov. 17, 2025.
Brief Summary: The aim of this study is to compare the efficacy, safety profile, pharmacokinetics, pharmacodynamics, and immunogenicity of BCD-281 and the reference drug in subjects with relapsing multiple sclerosis.
Study Start Date: Nov. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Relapsing-remitting Multiple Sclerosis (RRMS)
Intervention:
BIOLOGICAL: BCD-281
anti-CD20 monoclonal antibody
BIOLOGICAL: Ocrelizumab
anti-CD20 monoclonal antibody
Recruitment Status: RECRUITING
Sponsor: Biocad
Disclaimer...